

# Voice patterns as markers of schizophrenia: building a cumulative generalizable approach via a cross-linguistic and meta-analysis based investigation

Alberto Parola<sup>a, b, c</sup>, Ardis Simonsen<sup>b, d</sup>, Jessica Mary Lin<sup>a, b</sup>, Yuan Zhou<sup>e</sup>, Huiling Wang<sup>f</sup>,  
Shiho Ubukata<sup>g</sup>, Katja Koelkebeck<sup>h, i</sup>, Vibeke Bliksted<sup>b, d</sup>, Riccardo Fusaroli<sup>a, b, l</sup>

<sup>a</sup> Department of Linguistics, Cognitive Science and Semiotics, Aarhus University, Aarhus, Denmark

<sup>b</sup> The Interacting Minds Center - Institute of Culture and Society, Aarhus University, Aarhus, Denmark

<sup>c</sup> Department of Psychology, University of Turin, Turin, Italy

<sup>d</sup> Psychosis Research Unit - Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

<sup>e</sup> Institute of Psychology, Chinese Academy of Sciences, Beijing, China

<sup>f</sup> Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, China

<sup>g</sup> Department of Psychiatry, Kyoto University, Kyoto, Japan

<sup>h</sup> LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Hospital and Institute of the University of Duisburg-Essen, Essen, Germany

<sup>i</sup> Center for Translational Neuro- & Behavioral Sciences (C-TNBS), University Duisburg-Essen, Germany

<sup>l</sup> Linguistic Data Consortium, University of Pennsylvania, USA

Correspondence concerning this article should be addressed to:

Alberto Parola, Jens Chr. Skous Vej 2, 8000 Aarhus C, Denmark

Phone number: +390116703065

E-mail: [alberto.parola@cc.au.dk](mailto:alberto.parola@cc.au.dk)

Word counts abstract (max 250): 244

Word counts text body (max 4000): 3999

1

## Abstract

2 **Background and Hypothesis:** Voice atypicalities are potential markers of clinical features of  
3 schizophrenia (e.g., negative symptoms). A recent meta-analysis identified an acoustic profile  
4 associated with schizophrenia (reduced pitch variability and increased pauses), but also  
5 highlighted shortcomings in the field: small sample sizes, little attention to the heterogeneity  
6 of the disorder, and to generalizing findings to diverse samples and languages.

7

8 **Study Design:** We provide a critical cumulative approach to vocal atypicalities in  
9 schizophrenia, where we conceptually and statistically build on previous studies. We aim at  
10 identifying a cross-linguistically reliable acoustic profile of schizophrenia and assessing  
11 sources of heterogeneity (symptomatology, pharmacotherapy, clinical and social  
12 characteristics). We relied on previous meta-analysis to build and analyze a large cross-  
13 linguistic dataset of audio recordings of 231 patients with schizophrenia and 238 matched  
14 controls (>4.000 recordings in Danish, German, Mandarin and Japanese). We used multilevel  
15 Bayesian modeling, contrasting meta-analytically informed and skeptical inferences.

16

17 **Study Results:** We found only a minimal generalizable acoustic profile of schizophrenia  
18 (reduced pitch variability), while duration atypicalities replicated only in some languages. We  
19 identified reliable associations between acoustic profile and individual differences in clinical  
20 ratings of negative symptoms, medication, age and gender. However, these associations vary  
21 across languages.

22

23 **Conclusions:** The findings indicate that a strong cross-linguistically reliable acoustic profile  
24 of schizophrenia is unlikely. Rather, if we are to devise effective clinical applications able to  
25 target different ranges of patients, we need first to establish larger and more diverse cross-  
26 linguistic datasets, focus on individual differences, and build self-critical cumulative  
27 approaches.

28

29 *Keywords:*

30 vocal analysis, psychosis, speech signal, digital phenotyping, prosody, negative symptoms

31

32

1

## 2 **Introduction**

3 From its very first definitions, schizophrenia has been associated with voice  
4 atypicalities<sup>1,2</sup>, qualitatively described in terms of e.g., poverty of speech, increased pauses,  
5 distinctive tone and intensity of voice. A recent systematic meta-analysis<sup>3</sup> indicates a  
6 plausible acoustic profile associated with schizophrenia. In this study, we assess how  
7 generalizable that profile is within a large cross-linguistic dataset, as well as sources of  
8 heterogeneity in vocal patterns of patients with schizophrenia.

9 Atypical voice patterns are included amongst negative symptoms of schizophrenia,  
10 such as alogia and blunted affect, which are among the primary diagnostic criteria and  
11 prognostic indicators of the disorder (e.g. response to treatment and reduced likelihood of  
12 remission<sup>4-7</sup>). Vocal behavior may constitute a window into the underlying social and  
13 cognitive features of the disorder<sup>8</sup>. For example, the social and cognitive impairments  
14 frequently reported in schizophrenia<sup>9-11</sup> may be reflected in difficulties in speech fluency (e.g.  
15 increased pauses), or in controlling the voice to express affective and emotional contents and  
16 to mark relevant information<sup>12,13</sup>. In other words, not only can the quantitative analysis of  
17 vocal behavior scaffold the current evaluation of negative symptoms<sup>14-19</sup>, but it could also  
18 offer a more fine-grained perspective on its clinical, social and cognitive dimensions, e.g.,  
19 social and cognitive functioning over time<sup>8,18,20,21</sup>.

20 However, while extensive literature exists on vocal atypicalities in schizophrenia, with  
21 studies spanning back to the 60's, the findings are often contradictory and difficult to  
22 interpret. A recent meta-analysis<sup>3</sup> identified weak atypicalities in pitch variability - potentially  
23 related to flat affect- and stronger atypicalities in proportion of spoken time, speech rate, and  
24 pauses - potentially related to alogia and flat affect. The effects had large heterogeneity, and  
25 were modest compared to clinical judgments of vocal atypicalities<sup>22</sup>. The studies were noted

3

1 to have small sample sizes, high heterogeneity in methods and features analyzed, with little to  
2 no attention to the heterogeneity of the disorder<sup>23-25</sup> and to the replicability and  
3 generalizability of previous results on diverse samples<sup>20,25-27</sup>. Further, voice quality features -  
4 highlighted as important by speech pathologists and speech processing research<sup>28,29</sup> - had been  
5 largely neglected.

6 To assess the robustness and potential clinical impact of biobehavioral vocal markers  
7 of schizophrenia, we need to understand under which conditions they vary and under which  
8 they can be relied upon. We need to map which variations in clinical and socio-cognitive  
9 features might underlie voice atypicalities, and how stable they are across languages, time and  
10 recordings. For example, although vocal behavior has been shown to be influenced by  
11 linguistic and cultural factors, all studies of vocal markers of schizophrenia have investigated  
12 single monolingual samples. We need to assess how voice atypicalities relate to the  
13 development of the disorder, for instance, whether they are a long-term consequence of  
14 chronicity, already present at illness onset, and vary along with symptom severity, thus being  
15 potentially useful for tracking the development of the disorder and monitoring the  
16 symptomatology over time<sup>30-32</sup>. Another crucial issue is how antipsychotic drugs relate to  
17 these atypicalities and impact our ability to use them as biobehavioral markers. For example,  
18 effects of antipsychotic medication have been hypothesized to affect language in different  
19 ways, such as causing extrapyramidal motor symptoms or increasing negative symptoms by  
20 blocking dopamine receptors<sup>33</sup>.

21 In other words, there is a need for a more rigorous cumulative scientific approach to  
22 understand vocal and prosodic atypicalities in schizophrenia: the synthesis and integration of  
23 data across studies and laboratories, in order to assess which patterns might generalize across  
24 contexts and samples, identify possible sources of variation and improve estimations. In this  
25 work, we provide the first steps towards such an approach.

1 First, we made use of the recommendations developed in the previous meta-analysis<sup>3</sup>  
2 and collected a large dataset of multiple audio-recordings of patients with schizophrenia and  
3 controls in four different languages and three language families (Germanic, Mandarin-  
4 Chinese, Japonic). Such a setup provides a stronger basis for estimating the robustness of  
5 vocal atypicalities, within and between subjects and samples, as well as their variability.  
6 Further, this design allows us to explicitly compare results across different languages for the  
7 first time in schizophrenia, thus accounting for the natural differences in vocal patterns across  
8 languages.

9 Second, we provided a more systematic investigation of the acoustic features  
10 potentially associated with schizophrenia. While a previous meta-analysis<sup>3</sup> identified relevant  
11 estimates for a limited set of features ( $n = 8$ ), pertaining to pitch and rhythm, recent  
12 investigations into Parkinson's disease and depression<sup>28,34</sup> suggest that voice quality and  
13 articulatory features might have higher discriminative power compared to traditional acoustic  
14 features. In other words, they might be particularly involved in the mechanisms underlying  
15 the disorders. We therefore extended the acoustic features investigated to include them.

16 Third, we cumulatively build on previous findings by explicitly (but critically)  
17 including the meta-analytic findings in the statistical Bayesian analysis of the current study.  
18 This practice - referred to as "informed priors" or "posterior passing"<sup>35</sup> - allows us to directly  
19 estimate how well our results match previous findings and in which ways they deviate, but  
20 also potentially increases the precision of our estimates.

21 Fourth, we include a more comprehensive assessment of the patients' symptomatology  
22 and clinical profile. Specifically, we model the relationships between acoustic features and  
23 pharmacotherapy, relevant clinical aspects, demographic and social features, relationships that  
24 have rarely been jointly investigated in previous studies<sup>36</sup>.

1 Finally, we rely on an open methodology: not only do we carefully describe the  
2 methodology used and test the robustness of the results to variations in the methodology; but  
3 we also use open-source software, extracting the features in a reproducible manner with  
4 openly available scripts.

5 By providing an initial consolidation and test of acoustic atypicalities in schizophrenia  
6 that systematically builds on and extends the previous literature, we aim to set the foundations  
7 for more critical theory development, more cumulative and holistic approaches to the  
8 understanding of the underlying mechanisms and potentially the development of applications  
9 that constructively support clinical practices.

10

## 11 **Methods**

### 12 **Participants**

13 We collected a Danish (DK), German (GE), Chinese (CH), and Japanese (JP) cross-linguistic  
14 dataset involving 231 participants with schizophrenia (105 DK, 61GE, 51CH, 14JP) and 238  
15 matched controls (HC) (116DK, 62GE, 43CH, 17JP). The samples for the present study were  
16 collected in separate studies assessing mentalizing ability in patients with schizophrenia and  
17 healthy controls. Information on demographics, IQ, psychopathology, and social functioning  
18 is summarized in **Table 1**. Detailed information on each study is reported in the  
19 **Supplementary Material (SM) - S1**.

20

21 **Table 1.** Demographic and clinical characteristics of patients with schizophrenia and healthy controls (HC).

Corpus	Danish		German		Chinese		Japanese	
<b>Diagnosis</b>	SCZ N = 105	HC N = 116	SCZ N = 61	HC N = 62	SCZ N = 51	HC N = 43	SCZ N = 14	HC N = 17
<b>N. of recording</b>	N = 900	N = 989	N = 612	N = 609	N = 401	N = 340	N = 121	N = 144
<b>Age</b>	26.5 (8.82)	26.4 (8.96)	31.7 (9.92)	33.2 (8.79)	27.2 (7.25)	29.7 (8.72)	28.6 (6.71)	41.9 (13.7)

<b>Education</b>	12.9 (2.74)	14.9 (2.61)	12.1 (1.48)	12.3 (1.11)	12.7 (2.69)	14.1 (2.37)	11.9 (1.37)	14.7 (2.93)
<b>Sex (n. of females and %)</b>	45 (43%)	50 (43%)	22 (36%)	24 (38%)	23 (45%)	19 (44%)	4 (29%)	11 (65%)
<b>Verbal IQ</b>	89.13 (18.7)	102.12 (16.1)	112.0 (15.6)	116.5 (16.9)	96.3 (16.6)	100.27 (14.7)	NA	NA
<b>SANS total</b>	9.66 (4.41)	NA	NA	NA	7.61 (2.99)	NA	NA	NA
<b>SAPS total</b>	10.32 (4.91)	NA	NA	NA	7.23 (4.79)	NA	NA	NA
<b>PANSS total</b>	NA	NA	54.65 (10.63)	NA	75.79 (10.44)	NA	58.86 (15.25)	NA
<b>PANSS negative</b>	NA	NA	14.61 (4.19)	NA	20.09 (5.24)	NA	15.28 (3.95)	NA
<b>PANSS positive</b>	NA	NA	11.31 (3.13)	NA	18.51 (4.37)	NA	12.86 (4.10)	NA
<b>Illness duration (months)</b>	8.87 (6.68)	NA	54.38 (83.24)	NA	63.13 (68.87)	NA	83.86 (91.33)	NA
<b>PSP</b>	56.01 (15.70)	86.46 (6.72)	NA	NA	54.09 (8.02)	NA	NA	NA

1 **Note:** The table displays means and standard deviations of demographic (age, education and sex) and clinical information.  
2 Clinical symptoms were measured using the Scale for the Assessment of Negative Symptoms (SANS)<sup>37</sup>, the Scale for the  
3 Assessment of Positive Symptoms (SAPS)<sup>38</sup>, and the Positive and Negative Syndrome Scale (PANSS)<sup>39</sup>. Social functioning was  
4 measured using the Personal and Social Performance scale (PSP)<sup>40</sup>. NA = data not available; SCZ = patients with  
5 schizophrenia, HC = healthy controls.

6

## 7 **Voice recordings**

8 The dataset included a total of 2.034 recordings of individuals with schizophrenia (mean  
9 recording length = 17.3 seconds (sec), sd = 15.6sec) and 2.082 recordings of control  
10 participants (recording length = 18.5sec, sd = 12.7sec). Voice recordings were collected using  
11 the Animated Triangles Task (ATT)<sup>41,42</sup>. The task is generally used to measure theory of mind  
12 (ToM) and involves twelve video clips representing an interaction between animated  
13 geometrical shapes (triangles). The participants were asked to provide an interpretation of  
14 what was going on in each animation and their answers were audio-recorded. A detailed

1 description of the task and its validity for assessing speech production is included in **SM2**.  
2 Recording setting and experimental procedure are described in detail in **SM3**, and were kept  
3 constant across the different sites. All recordings were manually pre-processed to remove  
4 background noise and interviewer speech when present, and to ensure that all recordings  
5 analyzed had adequate audio quality. A full description of the process and of the extracted  
6 acoustic features is available in **SM3**.

## 7 **Statistical Modeling**

### 8 **Analysis of effect of diagnosis on acoustic features**

9 To estimate the differences between individuals with schizophrenia and HC in the different  
10 acoustic measures, we used Bayesian multilevel Gaussian regression models on the current  
11 data with each acoustic feature as outcome, and diagnosis (schizophrenia vs. HC) and  
12 language (DK, GE, CH, JP) as predictors. Within the same model, we separately assessed the  
13 effect of diagnosis for each language, and modeled varying effects of participants, i.e.,  
14 intercepts and slopes, separately for each group and language. For each acoustic feature, we  
15 built a first model with weakly informative priors, i.e., expectations of no effects of diagnosis,  
16 thus conservatively regularizing the model parameters, reducing overfitting and leading to  
17 improved predictions<sup>43</sup>. We then built a second model with an informed prior (when  
18 available), that is meta-analytic effect size (ES), and compared results across the two models.  
19 We aimed to assess whether the effects of diagnosis are robust across changes of priors, and  
20 whether the skeptical and informed priors led to more robust inference, that is, in lower  
21 estimated out-of-sample error - measured in terms of Leave-One-Out based stacking  
22 weights<sup>44</sup>. To evaluate the potential role of biological sex (male vs. female), age and level of  
23 intelligence, we built additional models, one per each moderator interacting with group  
24 separately in the four languages. We then reported the model estimates for the interaction,  
25 including credible (i.e., Bayesian confidence) intervals (CIs) and evidence ratios (ERs), i.e.,



1 evidence in favor of the effect observed against alternative hypotheses (see **SM4**). When ER  
2 was weak (below 10, that is, less than ten times as much evidence for the effect as for  
3 alternative hypotheses), we also calculated the ER in favor of the null hypothesis. Further  
4 details are presented in the **SM4**. In addition to the more traditional acoustic features included  
5 in the previous meta-analysis, we extracted 24 novel voice quality acoustic features including  
6 both spectral and glottal properties of voice<sup>28</sup>, for a total of 32 including those of rhythm.  
7 Median and interquartile range (IQR) were calculated for each of these measures (see **SM3**).  
8 We then estimated the differences between individuals with schizophrenia and HC for all  
9 measures (see **SM5**). We report additional analyses in **SM7** to assess the robustness of the  
10 findings: we repeat all analyses on audio segments of 6 sec. to control for recording length.  
11 The results generally support our main findings and we report here only qualitative  
12 divergences.

13 **The relationship between acoustic features and clinical features, pharmacotherapy and**  
14 **social functioning.**

15 To assess the relationship between acoustic features and clinical ratings, we built Bayesian  
16 multilevel regression models with each acoustic feature as outcome, and clinical features (one  
17 at a time) as ordinal predictors. We separately assessed the relationship between the different  
18 acoustic features and clinical ratings for each language, and modeled varying effects of  
19 participants, i.e., intercepts and slopes, separately for each language. This analysis was  
20 performed on the schizophrenia group only (see **SM4** for more details).

21 To assess the effect of medication, patients were divided into two categories based on the  
22 mechanism of action of antipsychotic medication<sup>45</sup>, namely patients with (1) low D2R  
23 occupancy, i.e., Clozapine, Olanzapine, Paliperidone, Quetiapine or (2) high D2R occupancy,  
24 i.e., Aripiprazole, Amisulpride, Risperidone, Ziprasidone, Sertindole (see **SM6**).  
25 Antipsychotic dose was converted to chlorpromazine (CPZ) equivalents<sup>46</sup>. We used Bayesian

1 multilevel regression models, as described above, with each acoustic feature as outcome, and  
2 antipsychotic medication (high D2R, low D2R) and language (DK, CH, GE) as predictors.  
3 For each acoustic feature we built a first model with weakly informative priors, that is  
4 expectations of no effects of medication, and we then built a second model with informed  
5 prior (relying on DeBoer et al. 2020<sup>33</sup>, see **SM6**). Our main aim was to assess the  
6 generalizability of previous findings on the effect of medication on speech production in  
7 schizophrenia, more than evaluating the causal pathways of medication on speech production,  
8 which would have required a larger sample and more detailed information on potential  
9 confounders (see discussion section). To assess the role of drug dosage, duration of illness  
10 (DUI) and social functioning (PSP scale), we built Bayesian multilevel regression models  
11 with each acoustic feature as outcome, and chlorpromazine equivalents, DUI and PSP scale  
12 score (one at a time) as predictors. We also compared acoustic patterns between patients with  
13 first-episode (FES) schizophrenia and chronic patients. We used Bayesian multilevel  
14 regression models with each acoustic feature as outcome, illness onset (FES patients, chronic  
15 patients and healthy controls) and language as predictors (see **SM6** for more details).  
16 The code used for the analysis and the extracted features are openly available (see **SM8**).

## 17 **Results**

### 18 **Effect of Diagnosis**

19 The detailed results and comparisons to meta-analytic effects are reported in **Table 2** and  
20 **Figure 1**. We only partially replicated previous meta-analytic findings: only reduced pitch  
21 variability was found across all datasets, and with smaller effect sizes. Duration atypicalities  
22 (reduced speech rate, increased pause duration) were replicated only in the German and  
23 Danish corpora, and with smaller effect sizes. We also identified a new potential marker  
24 across languages: longer utterance duration. In agreement with the inconsistent replications,  
25 meta-analytically informed models were more robust and generalizable to new data (LOO

1 weights for skeptic models above .75) only in about half of the models, indicating that meta-  
 2 analytic findings were not fully representative of the current samples.  
 3 Biological sex, age and level of intelligence of the participants also affected the group  
 4 differences, although inconsistently across languages.  
 5 Our results are generally confirmed when only the 6-second segments of the audio recordings  
 6 are analyzed, although with some differences: the results of the robustness analysis (see **SM7**)  
 7 tend to be more consistent with the results of the meta-analysis<sup>3</sup> (e.g., reduced speech rate also  
 8 in German, reduced speech percentage in Danish, no evidence of reduced pause duration in  
 9 Chinese and Japanese). Interestingly, the robustness analysis also showed that patients with  
 10 schizophrenia were more likely to give very short responses to the task than controls (total  
 11 recording duration < 6sec, see **SM7**).

12 **Table 2.** Estimated standardized mean difference (HC- schizophrenia) for the eight acoustic measures present  
 13 in the meta-analysis, as estimated separately by the meta-analytically informed and the skeptical models

Acoustic Features	Group (HC – SCZ)	Group * Biological sex (M-F)	Age	IQ
<b>Pitch Median</b>	MA priors = 0.25 (-0.72, 1.30)			
Skeptical DK	0.05 (-0.16 0.26) ER = 1.94 ER01 = 3.53	0.1 (-0.1 0.29) ER = 3.77	<b>0.02 (0 0.03) ER = 32.33</b>	0 (-0.01 0) ER = 2.09 ER01 = 119.29
Skeptical GE	-0.06 (-0.29 0.17) ER = 1.98 ER01 = 3.09	0.04 (-0.3 0.38) ER = 1.43 ER01 = 3.26	0 (-0.02 0.01) ER = 2 ER01 = 51.01	0 (-0.01 0.01) ER = 1.11 ER01 = 87.94
Skeptical CH	<b>0.25 (-0.05 0.55) ER = 11.05</b>	<b>0.28 (-0.01 0.57) ER = 16.76</b>	<b>0.02 (0 0.04) ER = 45.3</b>	0.01 (0 0.02) ER = 4.11
Skeptical JP	<b>-0.57 (-0.98 -0.13) ER = 58.88</b>	<b>0.63 (0.18 1.08) ER = 77.12</b>	-0.01 (-0.08 0.04) ER = 1.04 ER01 = 11.37	-0.01 (-0.86 0.82) ER = 1.01 ER01 = 0.93
Informed DK	0.07 (-0.15 0.28) ER = 2.3 ER01 = 3.35	NA	NA	NA
Informed GE	-0.04 (-0.26 0.18) ER = 1.58 ER01 = 3.97	NA	NA	NA
Informed CH	<b>0.28 (-0.02 0.57) ER = 15</b>	NA	NA	NA
Informed JP	<b>-0.44 (-0.86 0) ER = 19.2</b>	NA	NA	NA
<i>Stacking weight</i>	<b>Informed Model 1.00</b>			
<b>Pitch IQR</b>	MA priors = -0.55 (-1.06, 0.09)			
Skeptical DK	<b>-0.19 (-0.32 -0.05) ER = 62.29</b>	0.16 (-0.1 0.41) ER = 5.29	0.01 (0 0.02) ER = 9	0 (-0.01 0) ER = 3.76
Skeptical GE	<b>-0.29 (-0.46 -0.11) ER = 343.83</b>	-0.03 (-0.34 0.28) ER = 1.29 ER01 = 3.72	0 (-0.01 0.02) ER = 1.83 ER01 = 59.83	0 (-0.01 0.01) ER = 1.46 ER01 = 128.11
Skeptical CH	<b>-0.2 (-0.43 0.04) ER = 11.02</b>	0.03 (-0.4 0.46) ER = 1.25 ER01 = 1.33	0.01 (-0.01 0.03) ER = 5.49	0 (-0.01 0) ER = 3.22

Skeptical JP	<b>-0.5 (-0.85 -0.13) ER = 64.79</b>	0.09 (-0.59 0.77) ER = 1.43 ER01 = 1.75	0.01 (-0.02 0.03) ER = 1.92 ER01 = 27.15	0 (-0.82 0.83) ER = 1.01 ER01 = 0.97
Informed DK	<b>-0.24 (-0.37 -0.1) ER = 832.33</b>	NA	NA	NA
Informed GE	<b>-0.35 (-0.52 -0.19) ER = 9999</b>	NA	NA	NA
Informed CH	<b>-0.31 (-0.52 -0.1) ER = 134.14</b>	NA	NA	NA
Informed JP	<b>-0.57 (-0.84 -0.3) ER = 2499</b>	NA	NA	NA
<i>Stacking weight</i>	<b>Informed Model 1.00</b>			
<b>Speech Rate</b>	MA priors -0.75 (-1.51, 0.04)			
Skeptical DK	<b>-0.37 (-0.54 -0.22) ER = 9999</b>	0.22 (-0.09 0.53) ER = 6.99	0 (-0.02 0.01) ER = 1.21 ER01 = 57.1	0 (-0.01 0.01) ER = 1.98 ER01 = 109.93
Skeptical GE	<b>-0.12 (-0.35 0.1) ER = 4.46</b>	0.29 (-0.17 0.74) ER = 5.49	<b>0.01 (0 0.03) ER = 11.95</b>	0 (-0.01 0.01) ER = 1.09 ER01 = 105.22
Skeptical CH	0.07 (-0.18 0.32) ER = 2.09 ER01 = 2.94	-0.1 (-0.56 0.36) ER = 1.8 ER01 = 2.94	0.01 (-0.01 0.03) ER = 3.14	0 (0 0.01) ER = 5.52
Skeptical JP	0.13 (-0.28 0.55) ER = 2.43 ER01 = 1.68	-0.39 (-1.12 0.34) ER = 4.43	0.02 (-0.01 0.06) ER = 5.08	0 (-0.82 0.83) ER = 1.01 ER01 = 1
Informed DK	<b>-0.41 (-0.57 -0.25) ER = 9999</b>	NA	NA	NA
Informed GE	<b>-0.21 (-0.43 0) ER = 19.58</b>	NA	NA	NA
Informed CH	-0.04 (-0.28 0.19) ER = 1.62 ER01 = 19.09	NA	NA	NA
Informed JP	-0.19 (-0.58 0.19) ER = 3.77	NA	NA	NA
<i>Stacking weight</i>	<b>Skeptic Model 1.00</b>			
<b>Speech Percentage</b>	MA priors -1.26 (-2.26, 0.25)			
Skeptical DK	-0.02 (-0.19 0.15) ER = 1.4 ER01 = 4.7	-0.04 (-0.36 0.28) ER = 1.35 ER01 = 3.67	0 (-0.01 0.02) ER = 1.69 ER01 = 46.55	0 (-0.01 0.01) ER = 1.51 ER01 = 114.89
Skeptical GE	0.07 (-0.18 0.3) ER = 2.24 ER01 = 2.94	0.25 (-0.23 0.73) ER = 3.99	<b>0.02 (0 0.03) ER = 15.08</b>	0 (0 0.01) ER = 7.16
Skeptical CH	<b>0.43 (0.17 0.68) ER = 332.33</b>	-0.25 (-0.75 0.24) ER = 4.05	<b>0.02 (0 0.04) ER = 10.64</b>	<b>0.01 (0 0.02) ER = 13.86</b>
Skeptical JP	<b>0.34 (-0.07 0.75) ER = 10.82</b>	-0.22 (-0.95 0.48) ER = 2.28 ER01 = 1.47	<b>0.04 (0.01 0.07) ER = 43.05</b>	-0.01 (-0.82 0.8) ER = 1.02 ER01 = 1.02
Informed DK	-0.09 (-0.26 0.09) ER = 3.87	NA	NA	NA
Informed GE	-0.06 (-0.3 0.18) ER = 1.86 ER01 = 109.19	NA	NA	NA
Informed CH	<b>0.28 (0.02 0.53) ER = 24.91</b>	NA	NA	NA
Informed JP	-0.03 (-0.46 0.39) ER = 1.13 ER01 = 62.41	NA	NA	NA
<i>Stacking weight</i>	<b>Skeptic Model 0.50</b>			
<b>Pause Number</b>	MA priors 0.05 (-1.23, 1.13)			
Skeptical DK	<b>-0.18 (-0.31 -0.05) ER = 73.63</b>	0.34 (0.07 0.6) ER = 57.14	-0.01 (-0.02 0.01) ER = 5.33	0 (0 0.01) ER = 3.27
Skeptical GE	<b>-0.22 (-0.42 -0.02) ER = 32.22</b>	0.15 (-0.24 0.55) ER = 2.78 ER01 = 2.43	0.01 (0 0.03) ER = 7.36	0 (-0.01 0.01) ER = 2.06 ER01 = 99.91
Skeptical CH	-0.17 (-0.4 0.06) ER = 8.16	-0.34 (-0.77 0.1) ER = 8.99	0 (-0.02 0.02) ER = 1.23 ER01 = 41.58	0 (-0.01 0) ER = 5.31
Skeptical JP	-0.06 (-0.44 0.32) ER = 1.58 ER01 = 2.15	-0.28 (-0.97 0.43) ER = 2.94 ER01 = 1.35	<b>0.03 (0 0.06) ER = 20.1</b>	0 (-0.82 0.81) ER = 1.02 ER01 = 1.03
Informed DK	<b>-0.18 (-0.31 -0.04) ER = 64.36</b>	NA	NA	NA

Informed GE	<b>-0.21 (-0.41 -0.02) ER = 25.18</b>	NA	NA	NA
Informed CH	-0.16 (-0.4 0.08) ER = 6.82	NA	NA	NA
Informed JP	-0.05 (-0.42 0.32) ER = 1.38 ER01 = 2.24	NA	NA	NA
<i>Stacking weight</i>	<b>Skeptic Model 1.00</b>			
<b>Pause duration</b>	MA priors 1.89 (0.72, 3.21)			
Skeptical DK	<b>0.23 (0.09 0.38) ER = 180.82</b>	-0.13 (-0.41 0.14) ER = 3.48	0 (-0.02 0.01) ER = 1.93 ER01 = 53.4	0 (-0.01 0.01) ER = 1.34 ER01 = 103.28
Skeptical GE	<b>0.17 (-0.03 0.37) ER = 12.04</b>	-0.17 (-0.59 0.26) ER = 2.91 ER01 = 2.18	-0.01 (-0.03 0) ER = 9.73	0 (-0.01 0) ER = 1.97 ER01 = 110.6
Skeptical CH	<b>-0.19 (-0.42 0.03) ER = 11.5</b>	0.27 (-0.14 0.69) ER = 6.09	-0.02 (-0.04 0) ER = 8.67	0 (-0.01 0) ER = 2.71 ER01 = 85.99
Skeptical JP	<b>-0.3 (-0.65 0.07) ER = 10.52</b>	0.28 (-0.4 0.95) ER = 3.05	<b>-0.04 (-0.07 0) ER = 30.65</b>	0 (-0.82 0.81) ER = 1.02 ER01 = 1.02
Informed DK	<b>0.3 (0.16 0.44) ER = 4999</b>	NA	NA	NA
Informed GE	<b>0.31 (0.11 0.51) ER = 177.57</b>	NA	NA	NA
Informed CH	-0.02 (-0.24 0.21) ER = 1.36 ER01 = 4640.1	NA	NA	NA
Informed JP	0.17 (-0.21 0.58) ER = 3.08	NA	NA	NA
<i>Stacking weight</i>	<b>Informed Model 0.77</b>			
<b>Utterance Duration</b>	MA priors -0.13 (-1.571 1.342)			
Skeptical DK	<b>0.17 (0.02 0.33) ER = 29.12</b>	<b>-0.34 (-0.67 -0.02) ER = 23.57</b>	0.01 (-0.01 0.02) ER = 2.86 ER01 = 43.25	<b>-0.01 (-0.01 0) ER = 10.66</b>
Skeptical GE	<b>0.37 (0.15 0.58) ER = 332.33</b>	0.1 (-0.35 0.55) ER = 1.77 ER01 = 2.42	<b>0.01 (0 0.03) ER = 12.79</b>	0 (0 0.01) ER = 3.5
Skeptical CH	<b>0.21 (-0.03 0.44) ER = 12.39</b>	-0.17 (-0.56 0.23) ER = 3.29	0 (-0.01 0.01) ER = 2 ER01 = 64.92	0 (0 0.01) ER = 3.2
Skeptical JP	<b>0.81 (0.45 1.15) ER = 1427.57</b>	-0.05 (-0.84 0.72) ER = 1.13 ER01 = 1.52	<b>0.04 (0.01 0.07) ER = 42.29</b>	-0.01 (-0.84 0.82) ER = 1.01 ER01 = 0.96
Informed DK	<b>0.18 (0.02 0.34) ER = 27.65</b>	NA	NA	NA
Informed GE	<b>0.37 (0.16 0.58) ER = 475.19</b>	NA	NA	NA
Informed CH	<b>0.21 (-0.02 0.44) ER = 13.99</b>	NA	NA	NA
Informed JP	<b>0.89 (0.51 1.25) ER = 4999</b>	NA	NA	NA
<i>Stacking weight</i>	<b>Skeptic Model 1.00</b>			
<b>Number of Utterance</b>				
Skeptical DK	<b>-0.21 (-0.35 -0.07) ER = 171.41</b>	<b>0.37 (0.1 0.64) ER = 76.52</b>	-0.01 (-0.02 0.01) ER = 4.31	0 (0 0.01) ER = 3.39
Skeptical GE	<b>-0.23 (-0.43 -0.03) ER = 29.21</b>	0.18 (-0.22 0.58) ER = 3.37	0.01 (0 0.03) ER = 8.36	0 (0 0.01) ER = 2.45 ER01 = 97.14
Skeptical CH	-0.14 (-0.37 0.1) ER = 4.93	<b>-0.37 (-0.81 0.05) ER = 12.12</b>	0 (-0.02 0.02) ER = 1 ER01 = 41.2	0 (-0.01 0) ER = 5.51
Skeptical JP	-0.1 (-0.48 0.27) ER = 2.12 ER01 = 1.99	-0.34 (-1.02 0.33) ER = 3.78	<b>0.03 (0 0.06) ER = 11.5</b>	0 (-0.83 0.83) ER = 0.98 ER01 = 1.07
<b>Total Duration</b>				
Skeptical DK	-0.03 (-0.22 0.15) ER = 1.64 ER01 = 4.24	0.19 (-0.17 0.56) ER = 4.16	0 (-0.02 0.02) ER = 1.02 ER01 = 48.82	0 (0 0.01) ER = 2.19 ER01 = 141.8
Skeptical GE	0.01 (-0.19 0.22) ER = 1.17 ER01 = 3.93	0.14 (-0.27 0.53) ER = 2.56 ER01 = 2.56	0 (-0.01 0.02) ER = 1.92 ER01 = 45.72	0 (-0.01 0.01) ER = 1.2 ER01 = 110.36


<b>Skeptical CH</b>	<b>-0.21 (-0.43 0.02) ER = 13.06</b>	0.54 (0.11 0.97) ER = 50.02	0 (-0.02 0.02) ER = 1.19 ER01 = 41.85	0 (-0.01 0.01) ER = 1.18 ER01 = 100.72
Skeptical JP	-0.27 (-0.63 0.12) ER = 7.35	-0.08 (-0.72 0.55) ER = 1.42 ER01 = 1.75	<b>-0.03 (-0.06 0) ER = 17.66</b>	0 (-0.82 0.85) ER = 0.99 ER01 = 1.02

1 **Note:** The first column reports the main effect of the diagnostic group (across sex and age), respectively from  
2 the meta-analysis (MA), for the skeptical Danish (DK), German (GE), Chinese (CH) and Japanese (JP) models,  
3 and for the informed ones. The second column indicates the interaction between the effect of the diagnostic  
4 group and biological sex (male–female), that is, the difference in effect of group between the male and the  
5 female participants. The third column reports the interaction between the effect of diagnostic group and age,  
6 that is, the change in effect size as age increases by 1 standard deviation (SD). The fourth column reports the  
7 interaction between the effect of diagnostic group and level of intelligence (IQ), the change in effect size as IQ  
8 increases by 1 SD. ER indicates the evidence ratio for the difference, ER01 the evidence ratio for the null effect.  
9 Bold text indicates findings for which there is more than anecdotal evidence (evidence ratio above 10).  
10 Abbreviations: SCZ, schizophrenia; HC, healthy controls. NA = not applicable.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

1  
2  
3  
4  
5

**Figure 1.**



1

2



## 1 **Novel Acoustic features**

2 The detailed results are reported in **Table S5\_A**. Generally, we found some evidence for  
 3 reduced formants median frequency and formants variability, and for increased median  
 4 relative amplitude (H1H2) and reduced H1H2 variability. However, these findings are small  
 5 and not robust across languages. Results for the other novel features are very uncertain or  
 6 inconsistent across languages. As for more traditional features, we found that sex, age, and  
 7 level of intelligence again affect several differences.

## 8 **Effect of Symptoms**

9 Detailed results and comparison with meta-analytic findings are reported in **Table 3**. Clinical  
 10 features generally correlated with acoustic features, and these associations were in line with  
 11 meta-analytic priors. However, we did not find reliable and robust associations across all  
 12 languages. The associations are generally stronger for temporal-duration measures (lower  
 13 speech percentage, increased pause duration and reduced speech rate are associated with  
 14 higher flat affect, alogia and negative symptom severity), whereas pitch measures (median  
 15 and IQR) are more weakly associated with clinical ratings. Most of the correlations are  
 16 between small and moderate (5-16% of explained variance), and vary across languages and  
 17 rating scales.

18

19 **Table 3.** Estimated standardized relation between acoustic and clinical features. ER indicates the evidence ratio  
 20 for the difference, ER01 the evidence ratio for the null effect.

Rating scales	SANS	SAPS	SANS - Alogia	SANS - Flat affect
<b>Pitch Median</b>				
MA priors	0.096 [-0.158, 0.346]	-0.185 [-0.691, 0.316]		
Skeptical DK	-0.01 (-0.19 0.15) ER = 1.22 ER01 = 6.52	0.1 (-0.05 0.25) ER = 6.87	0.11 (-0.05 0.27) ER = 6.77	-0.04 (-0.19 0.11) ER = 2.01 ER01 = 6.14
Skeptical CH	-0.01 (-0.35 0.33) ER = 1.13 ER01 = 3.12	-0.07 (-0.3 0.14) ER = 2.34 ER01 = 4.07	-0.03 (-0.47 0.4) ER = 1.21 ER01 = 2.41	-0.15 (-0.45 0.15) ER = 4.39
Informed DK	-0.02 (-0.19 0.16) ER = 1.32 ER01 = 3.89	0.1 (-0.04 0.25) ER = 8.39		

17

Informed CH	0.04 (-0.26 0.34) ER = 1.54 ER01 = 2.16	-0.08 (-0.3 0.13) ER = 2.89 ER01 = 4.52		
<i>Stacking weight</i>	<b>Informed Model 1.00</b>	<b>Informed Model 0.56</b>		
<b>Pitch IQR</b>				
MA priors	-0.01 [-0.196, 0.144]	-0.027 [-0.686, 0.763]	-0.035 [-0.317, 0.22]	-0.106 [-0.262, -0.047]
Skeptical DK	0.01 (-0.02 0.05) ER = 2.91 ER01 = 24.69	-0.01 (-0.03 0.02) ER = 1.64 ER01 = 33.01	0.01 (-0.02 0.04) ER = 1.69 ER01 = 31.04	0 (-0.03 0.02) ER = 1.4 ER01 = 39.65
Skeptical CH	-0.06 (-0.25 0.1) ER = 2.48 ER01 = 5.84	-0.03 (-0.14 0.07) ER = 2.21 ER01 = 8.3	<b>-0.32 (-0.6 -0.1) ER = 124</b>	<b>-0.26 (-0.42 -0.11) ER = 599</b>
Informed DK	0.01 (-0.02 0.05) ER = 2.95 ER01 = 11.54	-0.01 (-0.03 0.02) ER = 1.62 ER01 = 51.25	0.01 (-0.02 0.04) ER = 1.66 ER01 = 20.87	0 (-0.03 0.02) ER = 1.45 ER01 = 16.74
Informed CH	-0.05 (-0.23 0.11) ER = 2.15 ER01 = 2.47	-0.03 (-0.14 0.07) ER = 2.24 ER01 = 11.95	<b>-0.3 (-0.53 -0.1) ER = 141.86</b>	<b>-0.24 (-0.39 -0.1) ER = 749</b>
<i>Stacking weight</i>	<b>Informed Model 1.00</b>	<b>Skeptic Model 1.00</b>	<b>Skeptic Model 1.00</b>	<b>Informed Model 1.00</b>
<b>Speech percentage</b>				
MA priors	-0.229 [-0.499, 0.035]		-0.413 [-0.723, -0.07]	-0.1 (-0.18 -0.01) ER = 34.29
Skeptical DK	<b>-0.12 (-0.23 -0.02) ER = 47.78</b>	0.04 (-0.05 0.13) ER = 3.37	-0.03 (-0.12 0.06) ER = 2.17 ER01 = 9.57	<b>-0.09 (-0.17 0) ER = 23.49</b>
Skeptical CH	-0.02 (-0.3 0.24) ER = 1.15 ER01 = 3.88	0.07 (-0.1 0.24) ER = 3.17	-0.11 (-0.46 0.21) ER = 2.48 ER01 = 2.76	-0.06 (-0.3 0.17) ER = 2.03 ER01 = 4.01
Informed DK	<b>-0.13 (-0.24 -0.02) ER = 51.63</b>	NA	-0.03 (-0.13 0.06) ER = 2.55 ER01 = 10.71	<b>-0.09 (-0.18 -0.01) ER = 31.97</b>
Informed CH	-0.05 (-0.33 0.2) ER = 1.62 ER01 = 3.16	NA	-0.18 (-0.54 0.14) ER = 4.28	-0.11 (-0.34 0.12) ER = 3.46
<i>Stacking weight</i>	<b>Informed Model 1.00</b>		<b>Informed Model 0.88</b>	<b>Informed Model 1.00</b>
<b>Speech rate</b>				
Skeptical DK	<b>-0.18 (-0.28 -0.1) ER = 1999</b>	-0.02 (-0.09 0.06) ER = 1.91 ER01 = 13.81	<b>-0.13 (-0.22 -0.05) ER = 499</b>	<b>-0.11 (-0.18 -0.04) ER = 332.33</b>
Skeptical CH	-0.15 (-0.38 0.05) ER = 8.09	0.05 (-0.09 0.19) ER = 2.87 ER01 = 6.31	<b>-0.22 (-0.54 0.06) ER = 9.64</b>	<b>-0.17 (-0.37 0.01) ER = 14.62</b>
<b>Pause duration</b>				
MA priors	0.302 [-0.199, 0.783]			
Skeptical DK	<b>0.06 (0.02 0.11) ER = 186.5</b>	0 (-0.03 0.04) ER = 1.16 ER01 = 29.07	<b>0.04 (0 0.08) ER = 24.1</b>	<b>0.03 (0 0.07) ER = 21.99</b>
Skeptical CH	-0.03 (-0.22 0.16) ER = 1.52 ER01 = 5.35	-0.02 (-0.14 0.11) ER = 1.43 ER01 = 8.44	-0.02 (-0.29 0.25) ER = 1.17 ER01 = 4.15	0.01 (-0.17 0.2) ER = 1.21 ER01 = 5.81
Informed DK	<b>0.07 (0.02 0.11) ER = 221.22</b>	NA	NA	NA
Informed CH	-0.03 (-0.23 0.18) ER = 1.42 ER01 = 6.85	NA	NA	NA
<i>Stacking weight</i>	<b>Informed Model 1.00</b>			
<b>Number of pauses</b>				

Skeptical DK	<b>-0.06 (-0.13 0.01)</b> ER = <b>10.11</b>	0.02 (-0.04 0.08) ER = 2.1 ER01 = 15.8	-0.03 (-0.09 0.03) ER = 3.6	<b>-0.05 (-0.11 0)</b> ER = <b>15.81</b>	
Skeptical CH	0.08 (-0.14 0.3) ER = 2.86 ER01 = 3.72	<b>-0.15 (-0.3 -0.01)</b> ER = <b>23.19</b>	0.19 (-0.05 0.46) ER = 9.71	0.08 (-0.08 0.26) ER = 3.91	
<b>Duration of utterance</b>					
Skeptical DK	<b>-0.07 (-0.13 -0.01)</b> ER = <b>67.97</b>	<b>-0.05 (-0.09 0)</b> ER = <b>16.7</b>	<b>-0.08 (-0.14 -0.03)</b> ER = <b>374</b>	-0.03 (-0.08 0.02) ER = 6.33	
Skeptical CH	-0.1 (-0.28 0.06) ER = 5.97	<b>0.1 (0 0.21)</b> ER = <b>19.76</b>	<b>-0.25 (-0.51 -0.04)</b> ER = <b>35.14</b>	<b>-0.18 (-0.34 -0.04)</b> ER = <b>49.85</b>	
<b>Number of utterances</b>					
Skeptical DK	<b>-0.06 (-0.13 0.01)</b> ER = <b>13.89</b>	0.01 (-0.05 0.07) ER = 1.43 ER01 = 18.21	-0.04 (-0.1 0.02) ER = 6.63	<b>-0.06 (-0.11 0)</b> ER = <b>20.82</b>	
Skeptical CH	0.06 (-0.15 0.28) ER = 2.24 ER01 = 4.43	<b>-0.15 (-0.3 -0.02)</b> ER = <b>27.99</b>	0.15 (-0.09 0.41) ER = 5.74	0.06 (-0.11 0.24) ER = 2.71 ER01 = 4.99	
<b>Rating scales</b>	<b>PANSS Total</b>	<b>PANSS Negative</b>	<b>PANSS Positive</b>	<b>PANSS Conversation</b>	<b>PANSS Blunted affect</b>
<b>Pitch Median</b>					
MA priors		0.096 [-0.158, 0.346]	-0.185 [-0.691, 0.316]		
Skeptical CH	-0.3 (-0.79 0.16) ER = 5.97	-0.14 (-0.46 0.17) ER = 3.31	-0.24 (-0.6 0.11) ER = 6.73	0 (-0.25 0.26) ER = 1.1 ER01 = 3.97	-0.07 (-0.37 0.22) ER = 1.85 ER01 = 3.26
Skeptical JP	-0.43 (-1.03 0.18) ER = 7	-0.4 (-1.01 0.23) ER = 6.36	<b>-0.51 (-1.11 0.08)</b> ER = <b>11.66</b>	NA	NA
Skeptical GE	-0.1 (-0.48 0.28) ER = 1.92 ER01 = 2.45	-0.03 (-0.34 0.27) ER = 1.29 ER01 = 3.41	<b>-0.34 (-0.71 -0.01)</b> ER = <b>21.56</b>	-0.12 (-0.3 0.06) ER = 6.52	0.26 (-0.14 0.73) ER = 5.87
Informed CH	NA	-0.1 (-0.4 0.2) ER = 2.32 ER01 = 1.83	-0.26 (-0.62 0.1) ER = 7.72	NA	NA
Informed JP	NA	-0.18 (-0.66 0.31) ER = 2.66 ER01 = 1.06	<b>-0.63 (-1.28 0.03)</b> ER = <b>16.7</b>	NA	NA
Informed GE	NA	-0.02 (-0.3 0.25) ER = 1.18 ER01 = 2.37	<b>-0.36 (-0.74 -0.03)</b> ER = <b>25.79</b>	NA	NA
		<b>Skeptic Model 1.00</b>	<b>Skeptic Model 1.00</b>		
<b>Pitch IQR</b>					
MA priors	-0.091 [-0.34, 0.15]	-0.01 [-0.196, 0.144]	-0.027 [-0.686, 0.763]	0 (-0.25 0.26) ER = 1.1 ER01 = 3.97	-0.07 (-0.37 0.22) ER = 1.85 ER01 = 3.26
Skeptical CH	0.23 (-0.11 0.56) ER = 6.95	-0.15 (-0.35 0.05) ER = 8.45	<b>0.4 (0.24 0.57)</b> ER = <b>Inf</b>	-0.1 (-0.24 0.03) ER = 9.45	-0.07 (-0.26 0.11) ER = 2.7 ER01 = 5.13
Skeptical JP	0.04 (-0.43 0.53) ER = 1.26 ER01 = 2.21	-0.08 (-0.61 0.45) ER = 1.5 ER01 = 1.84	0.06 (-0.44 0.56) ER = 1.44 ER01 = 2.01	NA	NA
Skeptical GE	<b>-0.16 (-0.33 0.01)</b> ER = <b>16.39</b>	<b>-0.27 (-0.44 -0.14)</b> ER = <b>1999</b>	-0.01 (-0.17 0.16) ER = 1.29 ER01 = 5.93	-0.04 (-0.13 0.04) ER = 4.15	-0.1 (-0.34 0.08) ER = 4.43
Informed CH	0.18 (-0.14 0.48) ER = 5.4	-0.13 (-0.3 0.05) ER = 7.08	<b>0.41 (0.25 0.59)</b> ER = <b>5999</b>	-0.1 (-0.24 0.03) ER = 8.85	-0.08 (-0.25 0.08) ER = 3.62
Informed JP	0 (-0.43 0.43) ER = 1.05 ER01 = 1.71	-0.05 (-0.39 0.29) ER = 1.42 ER01 = 1.18	0.06 (-0.5 0.63) ER = 1.38 ER01 = 2.72	NA	NA
Informed GE	<b>-0.15 (-0.32 0.01)</b> ER = <b>15.57</b>	<b>-0.25 (-0.39 -0.12)</b> ER = <b>1199</b>	-0.02 (-0.19 0.15) ER = 1.36 ER01 = 8.98	-0.05 (-0.13 0.03) ER = 4.63	-0.1 (-0.29 0.06) ER = 5.3
	<b>Informed Model 1.00</b>	<b>Skeptic Model 1.00</b>	<b>Skeptic Model 1.00</b>	<b>Skeptic Model 1.00</b>	<b>Informed Model 1.00</b>

<b>Speech percentage</b>					
MA priors		0.302 [-0.199, 0.783]			
Skeptical CH	0.03 (-0.45 0.5) ER = 1.18 ER01 = 2.06	<b>-0.31 (-0.62 0) ER = 18.05</b>	0.14 (-0.23 0.5) ER = 2.97 ER01 = 2.22	-0.15 (-0.38 0.07) ER = 7.02	-0.2 (-0.49 0.08) ER = 7.6
Skeptical JP	0.24 (-0.25 0.73) ER = 4.03	0.14 (-0.42 0.67) ER = 2.01 ER01 = 1.72	0.19 (-0.36 0.72) ER = 2.64 ER01 = 1.55	NA	NA
Skeptical GE	<b>-0.26 (-0.57 0.04) ER = 11.88</b>	-0.12 (-0.36 0.12) ER = 3.93	-0.11 (-0.38 0.17) ER = 2.91 ER01 = 3.11	<b>-0.17 (-0.32 -0.03) ER = 36.97</b>	-0.17 (-0.5 0.13) ER = 5.63
Informed CH	0.03 (-0.45 0.53) ER = 1.18 ER01 = 2.11	<b>-0.32 (-0.63 -0.02) ER = 22.35</b>	NA	<b>-0.19 (-0.42 0.03) ER = 11.88</b>	<b>-0.26 (-0.48 -0.05) ER = 51.63</b>
Informed JP	0.23 (-0.29 0.74) ER = 3.56	0 (-0.51 0.48) ER = 0.97 ER01 = 1.75	NA	NA	NA
Informed GE	<b>-0.26 (-0.57 0.04) ER = 11.42</b>	-0.14 (-0.38 0.08) ER = 5.51	NA	<b>-0.19 (-0.34 -0.04) ER = 56.14</b>	<b>-0.23 (-0.51 -0.03) ER = 34.71</b>
	<b>Informed Model 1.00</b>	<b>Informed Model 1.00</b>		<b>Skeptic Model 1.00</b>	<b>Informed Model 1.00</b>
<b>Speech Rate</b>					
Skeptical CH	<b>-0.38 (-0.76 -0.01) ER = 20.28</b>	-0.16 (-0.41 0.08) ER = 6.48	-0.01 (-0.28 0.27) ER = 1.13 ER01 = 3.78	-0.13 (-0.32 0.06) ER = 6.8	-0.11 (-0.35 0.11) ER = 3.74
Skeptical JP	0.26 (-0.28 0.8) ER = 3.98	0.15 (-0.46 0.74) ER = 2.05 ER01 = 1.44	0.3 (-0.28 0.84) ER = 4.45	NA	NA
Skeptical GE	<b>-0.39 (-0.69 -0.1) ER = 61.5</b>	<b>-0.24 (-0.47 -0.02) ER = 23.9</b>	-0.12 (-0.4 0.15) ER = 3.22	<b>-0.18 (-0.34 -0.04) ER = 51.63</b>	-0.21 (-0.55 0.08) ER = 8.01
<b>Mean Pause Duration</b>					
MA priors		0.302 [-0.199, 0.783]			
Skeptical CH	0.14 (-0.24 0.49) ER = 2.78 ER01 = 2.15	<b>0.38 (0.22 0.54) ER = 1199</b>	-0.12 (-0.39 0.15) ER = 3.39	<b>0.23 (0.1 0.36) ER = 351.94</b>	<b>0.26 (0.11 0.43) ER = 351.94</b>
Skeptical JP	<b>-0.5 (-0.96 -0.01) ER = 20.98</b>	-0.42 (-0.96 0.13) ER = 8.93	<b>-0.49 (-1.02) ER = 16.05</b>		
Skeptical GE	<b>0.11 (0.023) ER = 18.54</b>	<b>0.07 (-0.02 0.16) ER = 10.45</b>	0.02 (-0.09 0.13) ER = 1.85 ER01 = 9	<b>0.11 (0.04 0.17) ER = 299</b>	<b>0.11 (-0.01 0.28) ER = 15.48</b>
Informed CH	NA	<b>0.39 (0.24 0.55) ER = 5999</b>	NA	NA	NA
Informed JP	NA	-0.37 (-0.95 0.21) ER = 6.18	NA	NA	NA
Informed GE	NA	<b>0.07 (-0.01 0.16) ER = 10.83</b>	NA	NA	NA
		<b>Informed Model 1.00</b>			
<b>Pause Number</b>					
Skeptical CH	<b>-0.51 (-0.94 -0.08) ER = 33.09</b>	<b>-0.32 (-0.62 -0.04) ER = 29.15</b>	0.02 (-0.32 0.37) ER = 1.15 ER01 = 2.78	<b>-0.3 (-0.5 -0.09) ER = 92.75</b>	<b>-0.25 (-0.52 0) ER = 19.91</b>
Skeptical JP	0.24 (-0.26 0.73) ER = 3.94	0.14 (-0.41 0.67) ER = 2.07 ER01 = 1.79	0.33 (-0.2 0.81) ER = 6.23	NA	NA
Skeptical GE	<b>-0.2 (-0.39 -0.03) ER = 32.9</b>	<b>-0.12 (-0.26 0.02) ER = 12.95</b>	-0.02 (-0.19 0.14) ER = 1.52 ER01 = 5.83	<b>-0.14 (-0.23 -0.06) ER = 271.73</b>	<b>-0.15 (-0.39 0.03) ER = 11.35</b>
<b>Utterance duration</b>					
Skeptical CH	<b>0.3 (0 0.59) ER = 18.05</b>	<b>0.2 (0.02 0.38) ER = 29.61</b>	0.1 (-0.12 0.32) ER = 3.63	0.09 (-0.03 0.22) ER = 8.51	<b>0.19 (0.06 0.33) ER = 60.22</b>
Skeptical JP	0.06 (-0.44 0.54) ER = 1.5 ER01 = 1.96	-0.01 (-0.53 0.49) ER = 1.04 ER01 = 2.05	0.11 (-0.4 0.6) ER = 1.94 ER01 = 1.87	NA	NA

Skeptical GE	<b>-0.19 (-0.33 -0.07)</b> ER = <b>110.11</b>	<b>-0.17 (-0.29 -0.07)</b> ER = <b>544.45</b>	-0.07 (-0.21 0.06) ER = 4.38	<b>-0.07 (-0.14 0)</b> ER = <b>18.29</b>	-0.07 (-0.27 0.1) ER = 3.06
<b>Utterance Number</b>					
Skeptical CH	<b>-0.49 (-0.9 -0.07)</b> ER = <b>34.71</b>	<b>-0.34 (-0.62 -0.07)</b> ER = <b>40.1</b>	0.03 (-0.3 0.35) ER = 1.25 ER01 = 3.21	<b>-0.3 (-0.5 -0.11)</b> ER = <b>145.34</b>	<b>-0.24 (-0.5 -0.01)</b> ER = <b>21.47</b>
Skeptical JP	0.25 (-0.25 0.73) ER = 4.16	0.12 (-0.42 0.65) ER = 1.83 ER01 = 1.68	0.35 (-0.17 0.83) ER = 7.15	NA	NA
Skeptical GE	<b>-0.22 (-0.41 -0.03)</b> ER = <b>39</b>	<b>-0.14 (-0.29 0)</b> ER = <b>20.66</b>	-0.03 (-0.21 0.14) ER = 1.68 ER01 = 5.22	<b>-0.15 (-0.25 -0.07)</b> ER = <b>314.79</b>	<b>-0.15 (-0.38 0.04)</b> ER = <b>9.95</b>

1

2

3

4

5

6

7

### **Medication, duration of illness and social functioning (PSP)**

8

We found that medication was related to vocal patterns, but inconsistently across languages.

9

The more widespread patterns were that patients who use high D2R occupancy drugs,

10

compared to patients who use low D2R occupancy drugs, show reduced pitch variability,

11

higher number of pauses, longer utterance duration and higher speech rate. Further, higher

12

drug dosage (CPZ equivalents) was associated with lower pitch median, lower speech rate,

13

increased pause and utterance duration and reduced total number of words (see **Table S6\_B**).

14

We generally found no difference between patients with FES and patients with chronic

15

schizophrenia, and only weak evidence supporting a role of illness duration: acoustic

16

atypicalities are present already at disease onset and not just associated with a longer and

17

more severe course of the disorder (see **Table S6\_C**). Finally, we found that increased speech

18

percentage and reduced pause duration were associated with higher scores on PSP, although

19

only in the Danish corpus (see **Table S6\_D**).

20

### **Discussion**

21

In the present paper, we aimed at developing a critical, cumulative scientific approach to the

22

understanding of vocal and prosodic atypicalities in schizophrenia. Relying on a previous

23

meta-analysis<sup>3</sup> of the field, we systematically assessed the generalizability of established and

1 novel acoustic markers on a new large cross-linguistic dataset. We also assessed whether  
2 explicitly incorporating previous findings as informed priors would increase the  
3 generalizability of the results and provide additional insights on heterogeneity of the findings  
4 compared to previous literature.

### 5 **Is there a universal generalizable acoustic profile of schizophrenia?**

6 Our study assessed the generalizability of findings across a heterogeneous dataset (4 different  
7 languages). In other words, we assessed whether previous findings would be shown in a new  
8 study applying analogous experimental and/or statistical procedures, i.e., replication<sup>47</sup>, “to  
9 populations with for instance a different language, age distribution, or other demographic and  
10 clinical characteristics”, i.e., generalization<sup>48</sup>. We only found a minimal generalizable  
11 acoustic profile of schizophrenia: reduced pitch variability and increased utterance duration,  
12 albeit with modest effect sizes. Given the heterogeneity of previous studies and uncertainty  
13 about publication bias reported in a previous meta-analysis<sup>3</sup>, even these minimal cross-  
14 linguistically generalized findings are far from trivial.

15 One possible mechanism for the generalizable acoustic profile is a relation to negative  
16 symptoms, emotional and effort-related ones. Reduced pitch variability is related to monotone  
17 speech and flat affect<sup>49-51</sup>, and increased utterance duration to lower energy and increased  
18 vocal effort<sup>52,53</sup>. Further, the most promising of the novel features we investigated (e.g.,  
19 reduced formant frequency and increased H1H2, albeit not consistent across all languages)  
20 also fit this explanation<sup>54-56</sup>. Reduced formant frequencies have been found to be associated  
21 with clinical ratings of blunted affect and alogia in schizophrenia<sup>55</sup>, and a decrease in  
22 articulatory effort in patients with depression<sup>28</sup>. Furthermore, many studies in patients with  
23 depression have shown that an increase in H1H2 can be considered one of the acoustic  
24 indicators of breathiness and associated with psychomotor retardation<sup>57</sup>. However, we should

1 be skeptical of any simplistic explanation as yet, since we did not find a cross-linguistically  
2 robust association between these acoustic features and clinical ratings of negative symptoms.  
3 In particular, we argue that heterogeneity of the studies and samples has not been  
4 insufficiently accounted for, so far.

### 5 **Source of heterogeneity in the voice profiles of patients with schizophrenia**

6 The second crucial contribution of this study is highlighting the importance and complexity of  
7 clinical, socio-demographic, contextual (e.g., speech task) and linguistic differences in  
8 assessing vocal markers of schizophrenia.

### 9 **Clinical heterogeneity**

10 Individuals with schizophrenia present wildly heterogeneous constellations of clinical  
11 features: symptoms, onset and duration of the disorder, as well as medications<sup>24,27</sup>. Moreover,  
12 some of the clinical ratings are based on the perceptual assessment of speech features, and  
13 accordingly, we should expect acoustic heterogeneity co-varying with clinical  
14 heterogeneity<sup>36,54,55</sup>. Indeed, we found associations between acoustic parameters and clinical  
15 ratings, with duration aspects being more closely related to clinical ratings, in line with meta-  
16 analytic findings<sup>3</sup>. Lower proportion of speech and reduced speech rate, as well as longer  
17 pause duration were generally associated with higher ratings of negative symptoms and, in  
18 particular, alogia and flat affect.

19 However, the acoustic atypicalities were generally smaller than differences in clinical  
20 ratings<sup>33,43</sup>, and their relation to clinical ratings was often inconsistent across languages and  
21 rating scales. This might have several explanations. The first is that the acoustic features  
22 analyzed are only a subset of those actually used by clinicians to produce clinical ratings of  
23 alogia and blunted affect<sup>15</sup>. Different approaches using larger sets of acoustic features and  
24 machine learning techniques could be required to better characterize the acoustic markers of  
25 clinical ratings<sup>54-56</sup>. Second, the divergence between acoustic features and clinical ratings can

1 be explained by the fact that these two signals have different temporal (i.e., precision with  
2 respect to time) and spatial (i.e., precision with respect to environmental changes) resolution,  
3 thus expecting high convergence between the two may not be realistic<sup>49</sup>. Third, different  
4 clinical scales might not be fully overlapping in the symptoms they include and in their  
5 definition of the symptoms<sup>58,59</sup>, and linguistic and cultural differences may also affect the  
6 frequency, expression and rating of symptoms, thus generating several inconsistencies<sup>60,61</sup>.

7 Different clinical profiles also often imply different medication profiles, and different  
8 medications can differentially impact vocal production<sup>41</sup>. Indeed, D2R drug occupancy and  
9 medication dosage were shown to relate to acoustic patterns, albeit inconsistently across  
10 languages. This suggests that the field needs a more fine-grained assessment of the different  
11 medications involved in schizophrenia, its comorbidities and their impact on voice.

12 Finally, we found no differences between patients with FES and chronic patients, and  
13 a limited role of illness duration on acoustic profiles: vocal atypicalities are already present at  
14 the onset of the disease and not only associated with a longer and more severe course of the  
15 disorder, thus having the potential for tracking its development and monitoring the  
16 symptomatology over time.

### 17 **Socio-demographic heterogeneity**

18 Another crucial source of heterogeneity in acoustic patterns is socio-demographic  
19 heterogeneity. Indeed, we found several reliable effects of sex and age on vocal atypicalities.  
20 However, the picture is currently very sparse, and more than identifying systematic effects,  
21 we rather recommend socio-demographic variables be taken explicitly into account.  
22 Promising progress has been made in normative modeling<sup>62,63</sup>, which relies on large samples  
23 to provide expectations, accounting for clinical and socio-demographic features, and assess  
24 individual deviations from such expectations. This approach is particularly relevant in light of  
25 recent evidence showing how computational speech analysis may be prone to serious bias



1 determined by socio-demographic factors, such as racial identity<sup>64</sup>, as it may help to identify  
2 such potential bias. An alternative approach is to collect larger samples and use propensity  
3 scores<sup>65,66</sup> to better match patients and controls and account for potential confounders. These  
4 approaches may also help to tackle the problem of selection bias, as most previous studies  
5 have used convenience samples with relatively homogeneous clinical and sociodemographic  
6 features (e.g., chronic or FES patients), that may not be fully representative of the  
7 schizophrenia spectrum and its heterogeneity.

### 8 **Linguistic heterogeneity**

9 Not least, albeit previously neglected, linguistic and cultural differences can also play  
10 a role. We modeled each language separately to account for the heterogeneity in the different  
11 corpora, thus allowing us to compare results across languages. In general, we found that  
12 atypical voice patterns were more similar within Germanic (Danish and German) and non-  
13 Germanic (Japanese and Chinese) language families. The most prominent results of the  
14 previous meta-analysis<sup>3</sup> (reduced speech percentage and speech rate, longer pause duration)  
15 were not consistently found across all languages in our study. One possible source of this  
16 discrepancy is the amount of noise and bias present in previous studies. Meta-analyses are  
17 often afflicted by publication bias, and heterogeneous quality in the estimates being collated,  
18 which often results in consistent discrepancies with multi-lab replications<sup>67</sup>. However, a  
19 complementary explanation is that quantitative vocal aspects may vary with the languages  
20 being studied, and that vocal atypicalities reported to be abnormal in schizophrenia may not  
21 be universally expressed in the same way. For instance, prosodic use of speech rate and  
22 pauses to create emphasis may differ across languages. Thus, it is possible that decreased  
23 prosodic emphasis is a universal feature of schizophrenia, but the acoustic ways in which this  
24 can be measured vary across languages. Vocal patterns must also be considered in relation to

1 their cultural and linguistic context<sup>8,68</sup>, and the generalizability across social and linguistic  
2 groups should be systematically tested in future studies.

### 3 **Acoustic heterogeneity and speech task**

4 The use of a common standardized task (i.e., the ATT<sup>41</sup>) allowed us to compare voice patterns  
5 across the different corpora. This is particularly important considering that a previous meta-  
6 analysis<sup>3</sup> has shown that varying speech tasks may yield different outcomes, and recent  
7 studies further support this finding<sup>55,51</sup>. Further, our task included repeated measurements and  
8 allowed us to model intra-speaker variability, which previous studies found to be relevant<sup>69-</sup>  
9 <sup>71</sup>. Even by controlling for intra-speaker variability and keeping the task constant, we found  
10 large and important differences in voice patterns between the corpora. Further, we noticed  
11 that the patients produced very short responses (< 6 sec) much more frequently than controls,  
12 and when excluding these trials, we observed that results were more in line with meta-analytic  
13 findings<sup>3</sup>. This suggests that acoustic patterns may be task-related (with the task also  
14 interacting with language) and not robust across different tasks.

### 15 **Limitations and future perspectives**

16 The large differences in terms of the clinical and socio-demographic features within our  
17 corpus is a limitation of the present study. For example, the sample size differs across  
18 languages, and the samples in the different languages are not exactly matched in terms of the  
19 relevant clinical features, such as medication or symptom profiles. Thus, larger sample sizes  
20 might be more representative than smaller ones, and partially different subpopulations might  
21 be investigated across languages. Further, even if we kept the task and the experimental  
22 procedure constant across sites, a more controlled acoustic setting, with high-quality headset  
23 microphones placed at a constant distance from the mouth, would have allowed to further  
24 reduce potential differences across the different recording settings. This variability, albeit  
25 limited, between our corpora in terms of these features, may have contributed to the

1 differences in the main results; however, it also provided an opportunity to assess the  
2 generalizability of results across more varied conditions and thus provided more generalizable  
3 results. Moreover, although we collected a larger multilingual sample compared to previous  
4 studies<sup>3,72</sup>, an ideal sample systematically representative of the schizophrenic spectrum and its  
5 clinical and sociodemographic variability would be even larger<sup>63</sup>. Future efforts should thus  
6 be directed to build a large open cross-linguistic corpus of speech recordings of patients with  
7 schizophrenia able to capture linguistic, cultural, socio-economic and clinical variability. This  
8 multilingual corpus may represent an ideal benchmark dataset for testing the reliability and  
9 generalizability (e.g., out of sample predictability) of voice analysis results in schizophrenia<sup>73</sup>,  
10 and the necessary ground for assessing its clinical applicability<sup>74</sup>. Not least, future studies  
11 should focus more on cross-diagnostic comparisons aimed at capturing symptom dimensions  
12 which extend over a single disorder<sup>75,76</sup>, and implement longitudinal designs able to test more  
13 complex hypothesis on the interaction between antipsychotic medication type and dosage,  
14 clinical (e.g., illness severity and duration) and sociodemographic (e.g., sex differences<sup>77</sup>)  
15 characteristics, and speech production.

16 Another limitation is that we focused on single features as markers of schizophrenia, and did  
17 not vary the speech task. For example, the specific social context in which the speech task  
18 takes place, the social actors involved in it, and the communicative goal to be fulfilled can  
19 influence speech production and thus acoustic patterns. Speaking to a superior vs a peer,  
20 having a formal interview vs. an informal chat, all involve different prosodic patterns.  
21 Individual participants might perceive the experiment context differently from each other,  
22 some as more formal than others; and this is further complicated by cultural factors affecting  
23 how interactions with researchers are perceived and dealt with, and therefore the acoustic  
24 patterns. Further, linguistic and vocal patterns are inherently multidimensional, with different  
25 acoustic features interacting with each other, and cross-linguistic variations potentially

1 affecting these interactions. Looking at single features could thus be reductive: future studies  
2 should focus more on examining patterns of shared variance across features<sup>78-80</sup>, their  
3 relations with different speech tasks (in terms of social and cognitive demands)<sup>78,79</sup>, and with  
4 linguistic variability<sup>8,80</sup>. However, this would require testing more fine-grained hypotheses on  
5 mechanisms relying on formal linguistic theory<sup>68</sup> and on psychopathological functioning  
6 theory.

## 7 **Conclusion**

8 Overall, we found scarce evidence for a universal, distinctive vocal pattern that characterizes  
9 schizophrenia: vocal patterns are highly heterogeneous with different sources of heterogeneity  
10 interacting with each other at different levels. These results raise some questions on  
11 generalizability of previous findings and on the possibility to cumulatively build on them<sup>81</sup>.  
12 However, they also indicate where future attempts may be directed: a larger shared  
13 multilingual corpus representative of the heterogeneity of the schizophrenic spectrum, a more  
14 explicit focus on multidimensional acoustic patterns and their relations with speech tasks, and  
15 a self-correcting cumulative approach. These are the necessary conditions to develop effective  
16 clinical applications in the near future that can target different ranges of patients and address  
17 the issue of potential bias.

18

## 19 **Acknowledgments**

20 A.P is supported by a Marie Skłodowska-Curie Actions – H2020-MSCA-IF-2018 grant (ID:  
21 832518, Project: MOVES). A.S is supported by the Carlsberg Foundation. K. K has been  
22 supported by the Japan Society for the Promotion of Science (JSPS) (PE 07550). The project  
23 has been supported by seed funding from the Interacting Minds Center, Aarhus University.

24

25

26

1

2

3

4

## 5 **Bibliography**

- 6 1. Bleuler E, Aschaffenburg G. *Handbuch Der Psychiatrie*. (Deuticke, ed.); 1911.
- 7 2. Kraepelin E. *Dementia Praecox and Paraphrenia*. University of Edinburgh; 1919.
- 8 3. Parola A, Simonsen A, Bliksted V, Fusaroli R. Voice patterns in schizophrenia: A  
9 systematic review and Bayesian meta-analysis. *Schizophr Res*. Published online 2020.  
10 doi:10.1016/j.schres.2019.11.031
- 11 4. Couture SM, Granholm EL, Fish SC. A path model investigation of neurocognition,  
12 theory of mind, social competence, negative symptoms and real-world functioning in  
13 schizophrenia. *Schizophr Res*. 2011;125(2-3):152-160.  
14 doi:10.1016/j.schres.2010.09.020
- 15 5. Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S.  
16 Negative symptoms have greater impact on functioning than positive symptoms in  
17 schizophrenia: Analysis of CATIE data. *Schizophr Res*. 2012;137(1-3):147-150.  
18 doi:10.1016/j.schres.2012.01.015
- 19 6. Häfner H, Löffler W, Maurer K, Hambrecht M, An Der Heiden W. Depression,  
20 negative symptoms, social stagnation and social decline in the early course of  
21 schizophrenia. *Acta Psychiatr Scand*. 1999;100(2):105-118. doi:10.1111/j.1600-  
22 0447.1999.tb10831.x
- 23 7. Tandon R, Keshavan MS, Nasrallah H a. Schizophrenia, “just the facts” what we know  
24 in 2008. 2. Epidemiology and etiology. *Schizophr Res*. 2008;102(1-3):1-18.  
25 doi:10.1016/j.schres.2008.04.011

- 1 8. Palaniyappan L. More than a biomarker: could language be a biosocial marker of  
2 psychosis? *npj Schizophr* 2021 71. 2021;7(1):1-5. doi:10.1038/s41537-021-00172-1
- 3 9. Parola A, Berardinelli L, Bosco FM. Cognitive abilities and theory of mind in  
4 explaining communicative-pragmatic disorders in patients with schizophrenia.  
5 *Psychiatry Res.* 2018;260:144-151. doi:10.1016/j.psychres.2017.11.051
- 6 10. Bambini V, Arcara G, Bechi M, Buonocore M, Cavallaro R, Bosia M. The  
7 communicative impairment as a core feature of schizophrenia: Frequency of pragmatic  
8 deficit, cognitive substrates, and relation with quality of life. *Compr Psychiatry.*  
9 2016;71:106-120. doi:10.1016/j.comppsy.2016.08.012
- 10 11. Bliksted V, Fagerlund B, Weed E, Frith C, Videbech P. Social cognition and  
11 neurocognitive deficits in first-episode schizophrenia. *Schizophr Res.* 2014;153(1-3):9-  
12 17. doi:10.1016/j.schres.2014.01.010
- 13 12. Cohen AS, Dinzeo TJ, Donovan NJ, Brown CE, Morrison SC. Vocal acoustic analysis  
14 as a biometric indicator of information processing: Implications for neurological and  
15 psychiatric disorders. *Psychiatry Res.* 2015;226(1):235-241.  
16 doi:10.1016/j.psychres.2014.12.054
- 17 13. Cohen AS, McGovern JE, Dinzeo TJ, Covington MA. Speech deficits in serious  
18 mental illness: A cognitive resource issue? *Schizophr Res.* 2014;160(1-3):173-179.  
19 doi:10.1016/j.schres.2014.10.032
- 20 14. Insel TR. Digital Phenotyping: Technology for a New Science of Behavior. *JAMA.*  
21 2017;318(13):1215-1216. doi:10.1001/JAMA.2017.11295
- 22 15. Chandler C, Foltz PW, Cohen AS, et al. Machine learning for ambulatory applications  
23 of neuropsychological testing. *Intell Med.* 2020;1-2:100006.  
24 doi:10.1016/J.IBMED.2020.100006
- 25 16. Cohen AS, Cox CR, Masucci MD, et al. Digital Phenotyping Using Multimodal Data.

- 1            *Curr Behav Neurosci Reports*. 2020;7(4):212-220. doi:10.1007/S40473-020-00215-
- 2            4/FIGURES/3
- 3    17.    Ben-Zeev D, Brian R, Wang R, et al. CrossCheck: Integrating self-report, behavioral
- 4            sensing, and smartphone use to identify digital indicators of psychotic relapse.
- 5            *Psychiatr Rehabil J*. 2017;40(3):266-275. doi:10.1037/prj0000243
- 6    18.    Corcoran CM, Cecchi GA. Using Language Processing and Speech Analysis for the
- 7            Identification of Psychosis and Other Disorders. *Biol Psychiatry Cogn Neurosci*
- 8            *Neuroimaging*. 2020;5(8):770-779. doi:10.1016/j.bpsc.2020.06.004
- 9    19.    Galatzer-Levy IR, Abbas A, Koesmahargyo V, et al. Facial and vocal markers of
- 10            schizophrenia measured using remote smartphone assessments. *medRxiv*. 2020;1(646).
- 11            doi:10.1101/2020.12.02.20219741
- 12    20.    Hitczenko K, Mittal VA, Goldrick M. Understanding Language Abnormalities and
- 13            Associated Clinical Markers in Psychosis: The Promise of Computational Methods.
- 14            *Schizophr Bull*. 2021;47(2):344-362. doi:10.1093/SCHBUL/SBAA141
- 15    21.    Corcoran R, Frith CD. Autobiographical memory and theory of mind: Evidence of a
- 16            relationship in schizophrenia. *Psychol Med*. 2003;33(5):897-905.
- 17            doi:10.1017/S0033291703007529
- 18    22.    Cohen AS, Mitchell KR, Elvevåg B. What do we really know about blunted vocal
- 19            affect and alogia? A meta-analysis of objective assessments. *Schizophr Res*.
- 20            2014;159(2-3):533-538. doi:10.1016/j.schres.2014.09.013
- 21    23.    Schnack HG. Improving individual predictions: Machine learning approaches for
- 22            detecting and attacking heterogeneity in schizophrenia (and other psychiatric diseases).
- 23            *Schizophr Res*. 2019;214:34-42. doi:10.1016/J.SCHRES.2017.10.023
- 24    24.    Gratton C, Mittal VA. Embracing the Complexity of Heterogeneity in Schizophrenia:
- 25            A New Perspective From Latent Clinical-Anatomical Dimensions. *Schizophr Bull*.

- 1           2020;46(6):1337-1338. doi:10.1093/schbul/sbaa122
- 2   25.   Honnorat N, Dong A, Meisenzahl-Lechner E, Koutsouleris N, Davatzikos C.  
3           Neuroanatomical heterogeneity of schizophrenia revealed by semi-supervised machine  
4           learning methods. *Schizophr Res.* 2019;214:43-50.  
5           doi:10.1016/J.SCHRES.2017.12.008
- 6   26.   Fisher AJ, Medaglia JD, Jeronimus BF. Lack of group-to-individual generalizability is  
7           a threat to human subjects research. *Proc Natl Acad Sci U S A.* 2018;115(27):E6106-  
8           E6115. doi:10.1073/PNAS.1711978115/-/DCSUPPLEMENTAL
- 9   27.   Dickinson D, Pratt DN, Giangrande EJ, et al. Attacking Heterogeneity in  
10           Schizophrenia by Deriving Clinical Subgroups From Widely Available Symptom Data.  
11           *Schizophr Bull.* 2018;44(1):101-113. doi:10.1093/SCHBUL/SBX039
- 12   28.   Cummins N, Scherer S, Krajewski J, Schnieder S, Epps J, Quatieri TF. A review of  
13           depression and suicide risk assessment using speech analysis. *Speech Commun.*  
14           2015;71:10-49. doi:10.1016/J.SPECOM.2015.03.004
- 15   29.   Arora S, Baghai-Ravary L, Tsanas A. Developing a large scale population screening  
16           tool for the assessment of Parkinson's disease using telephone-quality voice. *J Acoust*  
17           *Soc Am.* 2019;(145(5)):2871-2884. doi:10.1121/1.5100272
- 18   30.   Ben-Zeev D, Buck B, Kopelovich S, Meller S. A technology-assisted life of recovery  
19           from psychosis. *npj Schizophr* 2019 51. 2019;5(1):1-4. doi:10.1038/s41537-019-0083-  
20           y
- 21   31.   Arevian AC, Bone D, Malandrakis N, et al. Clinical state tracking in serious mental  
22           illness through computational analysis of speech. *PLoS One.* 2020;15(1):e0225695.  
23           doi:10.1371/JOURNAL.PONE.0225695
- 24   32.   Tan EJ, Meyer D, Neill E, Rossell SL. Investigating the diagnostic utility of speech  
25           patterns in schizophrenia and their symptom associations. *Schizophr Res.* 2021;238:91-



- 1           98. doi:10.1016/J.SCHRES.2021.10.003
- 2    33.   de Boer JN, Voppel AE, Brederoo SG, Wijnen FNK, Sommer IEC. Language  
3           disturbances in schizophrenia: the relation with antipsychotic medication. *npj*  
4           *Schizophr.* 2020;6(1):1-9. doi:10.1038/s41537-020-00114-3
- 5    34.   Moro-Velazquez L, Gomez-Garcia JA, Arias-Londoño JD, Dehak N, Godino-Llorente  
6           JI. Advances in Parkinson’s Disease detection and assessment using voice and speech:  
7           A review of the articulatory and phonatory aspects. *Biomed Signal Process Control.*  
8           2021;66:102418. doi:10.1016/J.BSPC.2021.102418
- 9    35.   Brand CO, Ounsley JP, Van der Post DJ, Morgan TJH. Cumulative Science via  
10          Bayesian Posterior Passing. *Meta-Psychology.* 2019;3. doi:10.15626/mp.2017.840
- 11   36.   Oomen PP, de Boer JN, Brederoo SG, et al. Characterizing speech heterogeneity in  
12          schizophrenia-spectrum disorders. *J Psychopathol Clin Sci.* 2022;131(2):172-181.  
13          doi:10.1037/ABN0000736
- 14   37.   Andreasen NC. *Scale for the Assessment of Negative Symptom.* University of Iowa;  
15          1984.
- 16   38.   *Scale for the Assessment of Positive Symptoms (SAPS).* University of Iowa; 1984.
- 17   39.   Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for  
18          schizophrenia. *Schizophr Bull.* 1987;13(1):261-276. doi:10.1093/schbul/13.2.261
- 19   40.   Nasrallah H, Morosini P, Gagnon DD. Reliability, validity and ability to detect change  
20          of the Personal and Social Performance scale in patients with stable schizophrenia.  
21          *Psychiatry Res.* 2008;161(2):213-224. doi:10.1016/j.psychres.2007.11.012
- 22   41.   Abell F, Happé F, Frith U. Do triangles play tricks? Attribution of mental states to  
23          animated shapes in normal and abnormal development. *Cogn Dev.* Published online  
24          2000. doi:10.1016/S0885-2014(00)00014-9
- 25   42.   Castelli F, Happé F, Frith U, Frith C. Movement and Mind: A Functional Imaging

- 1 Study of Perception and Interpretation of Complex Intentional Movement Patterns.  
2 *Neuroimage*. 2000;12(3):314-325. doi:10.1006/NIMG.2000.0612
- 3 43. Gelman A, Vehtari A, Simpson D, et al. Bayesian Workflow. *arXiv Prepr*  
4 *arXiv201101808*. Published online November 3, 2020. doi:10.48550/arxiv.2011.01808
- 5 44. Yao Y, Vehtari A, Simpson D, Gelman A. Using Stacking to Average Bayesian  
6 Predictive Distributions (with Discussion). <https://doi.org/10.1214/17-BA1091>.  
7 2018;13(3):917-1007. doi:10.1214/17-BA1091
- 8 45. Aringhieri S, Carli M, Kolachalam S, et al. Molecular targets of atypical  
9 antipsychotics: From mechanism of action to clinical differences. *Pharmacol Ther*.  
10 2018;192:20-41. doi:10.1016/J.PHARMTHERA.2018.06.012
- 11 46. Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. Dose Equivalents for  
12 Second-Generation Antipsychotics: The Minimum Effective Dose Method. *Schizophr*  
13 *Bull*. 2014;40(2):314-326. doi:10.1093/SCHBUL/SBU001
- 14 47. Goodman SN, Fanelli D, Ioannidis JPA. What does research reproducibility mean? *Sci*  
15 *Transl Med*. Published online June 1, 2016:96-102.  
16 doi:10.1126/SCITRANSLMED.AAF5027
- 17 48. Vandembroucke JP, Von Elm E, Altman DG, et al. Strengthening the Reporting of  
18 Observational Studies in Epidemiology (STROBE): Explanation and Elaboration.  
19 *PLOS Med*. 2007;4(10):e297. doi:10.1371/JOURNAL.PMED.0040297
- 20 49. Cohen AS, Schwartz E, Le TP, et al. Digital phenotyping of negative symptoms: the  
21 relationship to clinician ratings. *Schizophr Bull*. 2021;47(1):44-53.  
22 doi:10.1093/schbul/sbaa065
- 23 50. Alpert M, Shaw RJ, Pouget ER, Lim KO. A comparison of clinical ratings with vocal  
24 acoustic measures of flat affect and alogia. *J Psychiatr Res*. 2002;36(5):347-353.  
25 doi:10.1016/S0022-3956(02)00016-X

- 1 51. Compton MT, Lunden A, Cleary SD, et al. The aprosody of schizophrenia:  
2 Computationally derived acoustic phonetic underpinnings of monotone speech.  
3 *Schizophr Res.* 2018;197:392-399. doi:10.1016/j.schres.2018.01.007
- 4 52. Beechey T, Buchholz JM, Keidser G. Measuring communication difficulty through  
5 effortful speech production during conversation. *Speech Commun.* 2018;100:18-29.  
6 doi:10.1016/J.SPECOM.2018.04.007
- 7 53. Traunmüller H, Eriksson A. Acoustic effects of variation in vocal effort by men,  
8 women, and children. *J Acoust Soc Am.* 2000;107(6):3438. doi:10.1121/1.429414
- 9 54. De Boer JN, Voppel AE, Brederoo SG, et al. Acoustic speech markers for  
10 schizophrenia-spectrum disorders: a diagnostic and symptom-recognition tool. *Psychol*  
11 *Med.* Published online 2021:1-11. doi:10.1017/S0033291721002804
- 12 55. Cohen AS, Cox CR, Le TP, et al. Using machine learning of computerized vocal  
13 expression to measure blunted vocal affect and alogia. *npj Schizophr* 2020 61.  
14 2020;6(1):1-9. doi:10.1038/s41537-020-00115-2
- 15 56. Tahir Y, Yang Z, Id DC, et al. Non-verbal speech cues as objective measures for  
16 negative symptoms in patients with schizophrenia. Published online 2019:1-17.
- 17 57. Asiaee M, Vahedian-azimi A, Atashi SS, Keramatfar A, Nourbakhsh M. Voice Quality  
18 Evaluation in Patients With COVID-19: An Acoustic Analysis. *J Voice.* Published  
19 online October 1, 2020. doi:10.1016/J.JVOICE.2020.09.024
- 20 58. Fried EI. The 52 symptoms of major depression: Lack of content overlap among seven  
21 common depression scales. *J Affect Disord.* 2017;208:191-197.  
22 doi:10.1016/J.JAD.2016.10.019
- 23 59. Micoulaud-Franchi J, Quiles C, Batail J, L'encephale CL-, 2018 undefined. Making  
24 psychiatric semiology great again: A semiologic, not nosologic challenge. *Elsevier.*  
25 doi:10.1016/j.encep.2018.01.007

- 1 60. Khan A, Yavorsky C, Liechti S, et al. A rasch model to test the cross-cultural validity  
2 in the positive and negative syndrome scale (PANSS) across six geo-cultural groups.  
3 *BMC Psychol* 2013 11. 2013;1(1):1-18. doi:10.1186/2050-7283-1-5
- 4 61. Aggarwal NK, Tao H, Xu K, Stefanovics E, Zhening L, Rosenheck RA. Comparing the  
5 PANSS in Chinese and American inpatients: Cross-cultural psychiatric analyses of  
6 instrument translation and implementation. *Schizophr Res*. 2011;132(2-3):146-152.  
7 doi:10.1016/J.SCHRES.2011.08.003
- 8 62. Marquand AF, Kia SM, Zabihi M, Wolfers T, Buitelaar JK, Beckmann CF.  
9 Conceptualizing mental disorders as deviations from normative functioning. *Mol*  
10 *Psychiatry* 2019 2410. 2019;24(10):1415-1424. doi:10.1038/s41380-019-0441-1
- 11 63. Marquand AF, Rezek I, Buitelaar J, Beckmann CF. Understanding Heterogeneity in  
12 Clinical Cohorts Using Normative Models: Beyond Case-Control Studies. *Biol*  
13 *Psychiatry*. 2016;80(7):552-561. doi:10.1016/J.BIOPSYCH.2015.12.023
- 14 64. Hitczenko K, Cowan HR, Goldrick M, Mittal VA. Racial and Ethnic Biases in  
15 Computational Approaches to Psychopathology. *Schizophr Bull*. 2022;48(2):285-288.  
16 doi:10.1093/SCHBUL/SBAB131
- 17 65. Ali MS, Prieto-Alhambra D, Lopes LC, et al. Propensity score methods in health  
18 technology assessment: Principles, extended applications, and recent advances. *Front*  
19 *Pharmacol*. 2019;10:973. doi:10.3389/FPHAR.2019.00973/BIBTEX
- 20 66. Gooden TE, Gardner M, Wang J, et al. The risk of mental illness in people living with  
21 HIV in the UK: a propensity score-matched cohort study. *Lancet HIV*. 2022;9(3):e172-  
22 e181. doi:10.1016/S2352-3018(21)00319-2
- 23 67. Kvarven A, Strømmland E, Johannesson M. Comparing meta-analyses and preregistered  
24 multiple-laboratory replication projects. *Nat Hum Behav*. 2020;4(4):423-434.  
25 doi:10.1038/s41562-019-0787-z

- 1 68. Çokal D, Zimmerer V, Turkington D, et al. Disturbing the rhythm of thought: Speech  
2 pausing patterns in schizophrenia, with and without formal thought disorder. *PLoS*  
3 *One*. 2019;14(5):1-14. doi:10.1371/journal.pone.0217404
- 4 69. Dellwo V, Leemann A, Kolly M-J. Rhythmic variability between speakers:  
5 Articulatory, prosodic, and linguistic factors. *J Acoust Soc Am*. 2015;137(3):1513.  
6 doi:10.1121/1.4906837
- 7 70. Kanber E, Lavan N, McGettigan C. Highly Accurate and Robust Identity Perception  
8 From Personally Familiar Voices. *J Exp Psychol Gen*. Published online 2021.  
9 doi:10.1037/XGE0001112
- 10 71. Kreiman J, Park SJ, Keating PA, Alwan A. The Relationship Between Acoustic and  
11 Perceived Intraspeaker Variability in Voice Quality. In: *In Sixteenth Annual*  
12 *Conference of the International Speech Communication Association*. ; 2015.
- 13 72. Cohen AS, Mitchell KR, Elvevåg B. What do we really know about blunted vocal  
14 affect and alogia? A meta-analysis of objective assessments. *Schizophr Res*.  
15 2014;159(2-3):533-538. doi:10.1016/j.schres.2014.09.013
- 16 73. Rocca R, Yarkoni T. Putting Psychology to the Test: Rethinking Model Evaluation  
17 Through Benchmarking and Prediction: <https://doi.org/10.1177/25152459211026864>.  
18 2021;4(3). doi:10.1177/25152459211026864
- 19 74. Loth E, Ahmad J, Chatham C, et al. The meaning of significant mean group differences  
20 for biomarker discovery. *PLOS Comput Biol*. 2021;17(11):e1009477.  
21 doi:10.1371/JOURNAL.PCBI.1009477
- 22 75. Stein F, Buckenmayer E, Brosch K, et al. Dimensions of Formal Thought Disorder and  
23 Their Relation to Gray- and White Matter Brain Structure in Affective and Psychotic  
24 Disorders. *Schizophr Bull*. 2022;48(4):902-911. doi:10.1093/SCHBUL/SBAC002
- 25 76. Tang SX, Hänsel K, Cong Y, et al. Latent Factors of Language Disturbance and

- 1 Relationships to Quantitative Speech Features. *medRxiv*. Published online April 1,  
2 2022:2022.03.31.22273263. doi:10.1101/2022.03.31.22273263
- 3 77. Brand BA, Haveman YRA, De Beer F, De Boer JN, Dazzan P, Sommer IEC.  
4 Antipsychotic medication for women with schizophrenia spectrum disorders. *Psychol*  
5 *Med*. 2022;52(4):649-663. doi:10.1017/S0033291721004591
- 6 78. Parola A, Gabbatore I, Berardinelli L, Salvini R, Bosco FM. Multimodal assessment of  
7 communicative-pragmatic features in schizophrenia: a machine learning approach. *npj*  
8 *Schizophr 2021 71*. 2021;7(1):1-9. doi:10.1038/s41537-021-00153-4
- 9 79. Parola A, Salvini R, Gabbatore I, Colle L, Berardinelli L, Bosco FM. Pragmatics,  
10 Theory of Mind and executive functions in schizophrenia: Disentangling the puzzle  
11 using machine learning. *PLoS One*. Published online 2020.  
12 doi:10.1371/journal.pone.0229603
- 13 80. Lau JCY, Patel S, Kang X, et al. Cross-linguistic patterns of speech prosodic  
14 differences in autism: A machine learning study. Pegoraro C, ed. *PLoS One*.  
15 2022;17(6):e0269637. doi:10.1371/JOURNAL.PONE.0269637
- 16 81. Parola A, Lin JM, Simonsen A, et al. Speech disturbances in schizophrenia: Assessing  
17 cross-linguistic generalizability of NLP automated measures of coherence. *Schizophr*  
18 *Res*. Published online August 1, 2022. doi:10.1016/J.SCHRES.2022.07.002
- 19  
20  
21  
22  
23  
24  
25

1

2

3

4

5 **Figure Legends**

6 **Figure 1.** Comparing meta-analysis, skeptical expectations and results. Each panel presents a  
7 separate acoustic measure, with the x-axis corresponding to standardized mean differences  
8 (schizophrenia - HC) equivalent to Hedges'  $g$ , with estimates above 0 indicating higher scores  
9 for patients with schizophrenia. The overlap between the skeptical and meta-analytic posterior  
10 distributions suggests no real advantage in using meta-analytic informed priors compared to  
11 skeptic ones.